Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273004 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL10631088 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL148701 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL993588 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL10579468 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL352163 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL8436544 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL6758775 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL22325587 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL7605212 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528755-B2 | Method of producing bio-derived branched alkyl glyceryl ether, and bio-derived branched alkyl glyceryl ether produced by said method | ADEKA CORPORATION (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250263362-A1 | METHOD OF PRODUCING BIO-DERIVED BRANCHED ALKYL GLYCERYL ETHER, AND BIO-DERIVED BRANCHED ALKYL GLYCERYL ETHER PRODUCED BY SAID METHOD | ADEKA CORPORATION (JP) | 2025-08-21 | — | — | US | disclosed |
| US-11525102-B2 | Metal-working fluid compositions and methods for making | KRATON POLYMERS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220195326-A1 | Metal-working Fluid Compositions and Methods for Making | KRATON POLYMERS LLC (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4015603-A1 | METAL-WORKING FLUID COMPOSITIONS AND METHODS FOR MAKING | Kraton Polymers Research B.V. (NL) | 2022-06-22 | — | — | EP | disclosed |
| CN-114644954-A | Metal working fluid composition and preparation method thereof | 克拉通聚合物研究有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-0606276-A1 | SUSPENSION AND AGGLOMERATION OF AMIDOPEROXYACIDS. | AKZO NOBEL NV (NL) | 1994-07-20 | — | — | EP | disclosed |
| WO-1993007120-A1 | SUSPENSION AND AGGLOMERATION OF AMIDOPEROXYACIDS | AKZO NOBEL N.V. (NL) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528755-B2 | Method of producing bio-derived branched alkyl glyceryl ether, and bio-derived branched alkyl glyceryl ether produced by said method | ADH5, ADH1A, ADH1C | EPHX1 197/4885FAAH 195/4885SMN1; SMN2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.